<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" href="./css/bootstrap.min.css">
    <link rel="stylesheet" href="./css/all.min.css">
    <link rel="stylesheet" href="./css/fontawesome.min.css">
    <link rel="stylesheet" href="./css/style.css">
    <title>Diabetes 360 eMagazine</title>
</head>
<body>


    <div class="container">
    <div class="main">
        <div class="left">
            <a href="./page-9.html"><img src="./img/prev.png" alt="previous"></a>
        </div>
        <div class="right">
            <a href="./page-11.html"><img src="./img/next.png" alt="next"></a>
        </div>
        
        <header class="pages-header-footer pages-h-f-white">
            <div class="row align-items-center m-0">
                <div class="col-3 header-txt header-txt-black"><p class=" m-0">NEWSLETTER in Diabetes</p></div>
                <div class="col-7 align-content-center"><div class="dark-line"></div></div>
                <div class="col-2"><img src="img/sanofi-logo-black.png" alt=""></div>
            </div>
        </header>
        <div class="article-head">
            <h1 class="headline"><span class="bold">Magnitude of Glycemic Improvement in Patients with
                Type 2 Diabetes Treated with Basal Insulin:</span>
                Subgroup Analyses from the MOBILE Study</h1>
                <hr>
            <div class="subheader">
                <p class="primary-col">
                    Source: Davis G, Bailey R, Calhoun P, Price D, Beck RW. Magnitude of Glycemic Improvement in Patients with Type 2 Diabetes Treated
                    with Basal Insulin: Subgroup Analyses from the MOBILE Study. Diabetes Technol Ther. 2022 May;24(5): 324-331
                </p>
            </div>
        </div>
        <article>
            <div class="row">
                <div class="col-lg-6 col-sm-12">
                    
                    <p>
                        The recent multicenter MOBILE clinical trial showed that
sustained use of real-time CGM (CGM) in participants with
type 2 diabetes treated with basal insulin in combination
with other noninsulin agents in a primary care setting
improved glycemic control during 8 months of follow-up.
Both HbA<sub>1c</sub> and mean glucose values after 8 months were
lower for participants using CGM compared to those using
self-monitoring of blood glucose with a blood glucose
meter (BGM). To further evaluate the magnitude of the
effect of CGM on glycemic control among adults with
poorly controlled type 2 diabetes treated with basal insulin,
Davis et al., examined data from the MOBILE trial stratified
according to underlying glycemic control metrics at
baseline. The investigators hypothesized that participants
with worse control at baseline (by HbA<sub>1c</sub> and CGM timein-
range 70–180 mg/dL [TIR] categories) would have the
greatest benefit from adding CGM to their diabetes care
over 8 months of follow-up.
                    </p>
                        <p>
                            To this end, they conducted a post hoc analysis of the
MOBILE Study, a multicenter trial examining the impact
of CGM versus self-monitoring with a blood glucose meter
(BGM) in patients with type 2 diabetes treated with basal
insulin without prandial insulin.
                        </p>
                        <p>
                            As previously reported, the MOBILE trial included 175 adults
with type 2 diabetes using basal insulin, with 116 randomly
assigned to the CGM group and 59 to the BGM group. Mean
age was 57 years (range 33 to 79); 50% were female. The
race/ethnicity distribution was 47% white, 28% Hispanic, 18%
black, 5% Asian, and 2% other. Mean (±standard deviation
[SD]) baseline HbA<sub>1c</sub> was 9.1% ± 0.9% and mean (±SD) baseline
TIR 70–180 mg/dL was 40% ± 25%. Potential participants were
recruited from primary care practices and were not under
the care of an endocrinologist to manage their diabetes.
                        </p>
    
                        <p>
                            Participants could not have been using prandial insulin
at the time of enrollment. Participants were divided into
subgroups based on baseline hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) and
baseline time-in-range 70-180 mg/dL (TIR). Change in TIR
from baseline was calculated within each subgroup.
                        </p>

                        <p>
                            In subgroups based on baseline HbA<sub>1c</sub>, compared with the
BGM group, the CGM group had 14% greater increase in
TIR for participants with baseline HbA<sub>1c</sub> ≥8.5%, 14% greater
increase for baseline HbA<sub>1c</sub> ≥9.0%, 22% greater increase for
                        </p>
                        
                </div>
    
                <div class="col-lg-6 col-sm-12">
                    <p>
                        baseline HbA<sub>1c</sub> ≥9.5%, and 32% greater increase for baseline
HbA<sub>1c</sub> ≥10.0% (P-value for interaction = 0.27).
                    </p>
                    <p>
                        The time spent with glucose >250 mg/dL was significantly
lower with CGM compared with BGM among participants
with higher HbA<sub>1c</sub> values (P for interaction = 0.004). Results
in subgroups based on baseline TIR paralleled the results in
subgroups based on baseline HbA<sub>1c</sub>.
                    </p>
                    <p>
                        Mean glucose over 24 h by baseline HbA<sub>1c</sub>. For those with
baseline HbA<sub>1c</sub> &lt;8.5%, mean glucose at baseline was 169 mg/
dL in the CGM and BGM groups. For those with baseline
HbA<sub>1c</sub> 8.5% to &lt;9.5%, mean glucose at baseline was 203 and
206 mg/dL in the CGM and BGM groups, respectively. For
those with baseline HbA<sub>1c</sub> ≥9.5%, mean glucose at baseline
was 242 and 245 mg/dL in the CGM and BGM groups,
respectively.
                    </p>

                    <p>
                        This post hoc analysis of the MOBILE trial demonstrated
that among participants with worse glycemic control at
baseline, the use of CGM was associated with a substantial
increase in TIR and reduction in HbA<sub>1c</sub> compared with use
of BGM alone. The most remarkable benefit from CGM in
those with the highest baseline HbA<sub>1c</sub> values appears to be
a reduction in time spent with glucose values exceeding
250 mg/dL.
                    </p>


                    <div class="purple-quote primary-bg">
                        <div class="quotes"><img src="./img/quotes.png" alt=""></div>
                        <h3>Conclusion</h3>
                        <p>
                            While the benefit of CGM on TIR among
patients with type 2 diabetes treated with
basal insulin is apparent across the range of
baseline glycemic control, the greatest impact
of CGM is in those with the worst baseline
glycemic control, particularly among those
with HbA<sub>1c</sub> ≥10%.
Overall, the findings of this post hoc analysis
suggest trends of greater treatment effect
on glycemic control outcomes with CGM
compared with BGM in those with worse
baseline glycemic control, similar to what
has been observed with other therapeutic
interventions. It is possible that behavior
modifications prompted by real-time glucose
data can provide significant additive glycemic
control benefit among patients with very high
initial HbA<sub>1c</sub> on less intensive insulin regimens.
                        </p>
                    </div>
                    
                </div>
            </div>
            
            <div class="article-footer">
                <div class="row">
                    <div class="col-lg-6 col-sm-12">
                        <div class="ref-rating">
                            <p>
                                BGM, blood glucose meter; CGM, continuous glucose monitoring; HbA<sub>1c</sub>,
hemoglobin A<sub>1c</sub>; TIR, time-in-range
                            </p>                    
                        </div>
                        <div class="rating">
                            <p>How do you rate this article?</p>
                            <div class="row px-4">
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=1" target="_blank"><img src="./img/red-1.png" alt="rate1"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=2" target="_blank"><img src="./img/orange-2.png" alt="rate2"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=3" target="_blank"><img src="./img/mustard-3.png" alt="rate3"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=4" target="_blank"><img src="./img/yellow-4.png" alt="rate4"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=5" target="_blank"><img src="./img/green-5.png" alt="rate5"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=6" target="_blank"><img src="./img/turquoise-6.png" alt="rate6"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=3" target="_blank"><img src="./img/aquamarine-7.png" alt="rate7"></a></div>
                            </div>
                            <div class="rating-bar">
                                <img src="./img/rating-1-5.png" alt="">
                            </div>  
                        </div>
                    </div>
                </div>
            </div>
        </article>
        </div>
        <footer class="footer">
            <div class="pages-header-footer">
                <div class="row">
                    <div class="col-1">
                        <div class="pagination">
                            <p>10</p>
                        </div>
                    </div>
                    <div class="col-8 align-content-center p-0">
                        <div class="dark-line"></div>
                    </div>
                    <div class="col-3 d-flex justify-content-center align-items-center">
                        <div class="header-txt-black header-txt">The 360 e-Magazine</div>
                    </div>
                </div>
            </div>
        
    </footer>

        </div>

    </div>    
    </div>


    <script src="./js/bootstrap.bundle.min.js"></script>
    </body>
</html>